Non-viral Pathogens of Infectious Diarrhoea Post-allogeneic Stem Cell Transplantation Are Associated with Graft-versus-host Disease

Overview

Journal Ann Hematol

Specialty Hematology

Date 2023 Nov 5

PMID 37926752

Authors

Matthew J Rees

Alexandra Rivalland

Sarah Tan

Mingdi Xie

Michelle K Yong

David Ritchie

Affiliations

Soon will be listed here.

Abstract

Infectious diarrhoea is common post-allogeneic haematopoietic stem-cell transplantation (alloHSCT). While the epidemiology of Clostridioides difficile infection (CDI) post-alloHSCT has been described, the impact of other diarrhoeal pathogens is uncertain. We reviewed all alloHSCT between 2017 and 2022 at a single large transplant centre; 374 patients were identified and included. The 1-year incidence of infectious diarrhoea was 23%, divided into viral (13/374, 3%), CDI (65/374, 17%) and other bacterial infections (16/374, 4%). There was a significant association between infectious diarrhoea within 1 year post-transplant and the occurrence of severe acute lower gastrointestinal graft-versus-host disease (GVHD, OR = 4.64, 95% CI 2.57-8.38, p < 0.001) and inferior GVHD-free, relapse-free survival on analysis adjusted for age, donor type, stem cell source and T-cell depletion (aHR = 1.64, 95% CI = 1.18-2.27, p = 0.003). When the classes of infectious diarrhoea were compared to no infection, bacterial (OR = 6.38, 95% CI 1.90-21.40, p = 0.003), CDI (OR = 3.80, 95% CI 1.91-7.53, p < 0.001) and multiple infections (OR = 11.16, 95% CI 2.84-43.92, p < 0.001) were all independently associated with a higher risk of severe GI GVHD. Conversely, viral infections were not (OR = 2.98, 95% CI 0.57-15.43, p = 0.20). Non-viral infectious diarrhoea is significantly associated with the development of GVHD. Research to examine whether the prevention of infectious diarrhoea via infection control measures or modulation of the microbiome reduces the incidence of GVHD is needed.

References

Kolb H, Mittermuller J, Clemm C, Holler E, Ledderose G, Brehm G . Donor leukocyte transfusions for treatment of recurrent chronic myelogenous leukemia in marrow transplant patients. Blood. 1990; 76(12):2462-5. View

Jagasia M, Arora M, Flowers M, Chao N, McCarthy P, Cutler C . Risk factors for acute GVHD and survival after hematopoietic cell transplantation. Blood. 2011; 119(1):296-307. PMC: 3251233. DOI: 10.1182/blood-2011-06-364265. View

El-Jawahri A, Li S, Antin J, Spitzer T, Armand P, Koreth J . Improved Treatment-Related Mortality and Overall Survival of Patients with Grade IV Acute GVHD in the Modern Years. Biol Blood Marrow Transplant. 2016; 22(5):910-8. DOI: 10.1016/j.bbmt.2015.12.024. View

Weisdorf D, Zhang M, Arora M, Horowitz M, Rizzo J, Eapen M . Graft-versus-host disease induced graft-versus-leukemia effect: greater impact on relapse and disease-free survival after reduced intensity conditioning. Biol Blood Marrow Transplant. 2012; 18(11):1727-33. PMC: 3472079. DOI: 10.1016/j.bbmt.2012.06.014. View

Garnett C, Apperley J, Pavlu J . Treatment and management of graft-versus-host disease: improving response and survival. Ther Adv Hematol. 2013; 4(6):366-78. PMC: 3854558. DOI: 10.1177/2040620713489842. View

Hahn T, McCarthy Jr P, Zhang M, Wang D, Arora M, Frangoul H . Risk factors for acute graft-versus-host disease after human leukocyte antigen-identical sibling transplants for adults with leukemia. J Clin Oncol. 2008; 26(35):5728-34. PMC: 2645611. DOI: 10.1200/JCO.2008.17.6545. View

Alonso C, Treadway S, Hanna D, Huff C, Neofytos D, Carroll K . Epidemiology and outcomes of Clostridium difficile infections in hematopoietic stem cell transplant recipients. Clin Infect Dis. 2012; 54(8):1053-63. PMC: 3309884. DOI: 10.1093/cid/cir1035. View

Van Praet J, Huysman A, De Knijf E, De Buyser S, Snauwaert S, van Droogenbroeck J . Infectious diarrhea after allogeneic hematopoietic cell transplantation assessed by a multiplex polymerase chain reaction assay. Int J Infect Dis. 2022; 127:17-22. DOI: 10.1016/j.ijid.2022.11.045. View

Kelly C, Lamont J . Clostridium difficile--more difficult than ever. N Engl J Med. 2008; 359(18):1932-40. DOI: 10.1056/NEJMra0707500. View

10.

Slimings C, Armstrong P, Beckingham W, Bull A, Hall L, Kennedy K . Increasing incidence of Clostridium difficile infection, Australia, 2011-2012. Med J Aust. 2014; 200(5):272-6. DOI: 10.5694/mja13.11153. View

11.

Bhutani D, Jaiyeoba C, Kim S, Naylor P, Uberti J, Ratanatharathorn V . Relationship between clostridium difficile infection and gastrointestinal graft versus host disease in recipients of allogeneic stem cell transplantation. Bone Marrow Transplant. 2018; 54(1):164-167. PMC: 6844071. DOI: 10.1038/s41409-018-0270-x. View

12.

Chakrabarti S, Lees A, Jones S, Milligan D . Clostridium difficile infection in allogeneic stem cell transplant recipients is associated with severe graft-versus-host disease and non-relapse mortality. Bone Marrow Transplant. 2000; 26(8):871-6. DOI: 10.1038/sj.bmt.1702627. View

13.

Ramanathan M, Kim S, He N, Chen M, Hematti P, Abid M . The incidence and impact of clostridioides difficile infection on transplant outcomes in acute leukemia and MDS after allogeneic hematopoietic cell transplant-a CIBMTR study. Bone Marrow Transplant. 2022; 58(4):360-366. PMC: 10079570. DOI: 10.1038/s41409-022-01896-z. View

14.

de La Cochetiere M, Durand T, Lalande V, Petit J, Potel G, Beaugerie L . Effect of antibiotic therapy on human fecal microbiota and the relation to the development of Clostridium difficile. Microb Ecol. 2008; 56(3):395-402. DOI: 10.1007/s00248-007-9356-5. View

15.

Sehgal K, Khanna S . Gut microbiome and infection: a closer look at the microscopic interface. Therap Adv Gastroenterol. 2021; 14:1756284821994736. PMC: 7905718. DOI: 10.1177/1756284821994736. View

16.

Rea M, OSullivan O, Shanahan F, OToole P, Stanton C, Ross R . Clostridium difficile carriage in elderly subjects and associated changes in the intestinal microbiota. J Clin Microbiol. 2011; 50(3):867-75. PMC: 3295116. DOI: 10.1128/JCM.05176-11. View

17.

Nelson A, Walk S, Taube S, Taniuchi M, Houpt E, Wobus C . Disruption of the human gut microbiota following Norovirus infection. PLoS One. 2012; 7(10):e48224. PMC: 3484122. DOI: 10.1371/journal.pone.0048224. View

18.

Hoyt R, Ritchie D, Roberts A, MacGregor L, Curtis D, Szer J . Cyclosporin, methotrexate and prednisolone for graft-versus-host disease prophylaxis in allogeneic peripheral blood progenitor cell transplants. Bone Marrow Transplant. 2008; 41(7):651-8. DOI: 10.1038/sj.bmt.1705955. View

19.

Glucksberg H, Storb R, Fefer A, Buckner C, Neiman P, Clift R . Clinical manifestations of graft-versus-host disease in human recipients of marrow from HL-A-matched sibling donors. Transplantation. 1974; 18(4):295-304. DOI: 10.1097/00007890-197410000-00001. View

20.

Yolken R, Bishop C, Townsend T, Bolyard E, Bartlett J, SANTOS G . Infectious gastroenteritis in bone-marrow-transplant recipients. N Engl J Med. 1982; 306(17):1009-2. DOI: 10.1056/NEJM198204293061701. View